Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2023; 19: e-20230438
DOI: 10.5935/2526-8732.20230438
Original Article
Surgical Oncology

Impact of advanced prostatic cancer treatment on quality of life and sexual function

Impacto do tratamento avançado do câncer de próstata na qualidade de vida e na função sexual
Fernando Parma Marsicano 
1   Federal University of Minas Gerais, Surgery department, Belo Horizonte - MG, Brazil
,
Andy Petroianu
1   Federal University of Minas Gerais, Surgery department, Belo Horizonte - MG, Brazil
› Author Affiliations Financial support: none to declare.
› Further Information
   Permissions and Reprints All articles of this category

ABSTRACT

Introduction: The studying the quality of life after cancer treatment has become a priority in oncology.

Objectives: To evaluate the impact of different treatments for recurrence prostate cancer on quality of life and sexual activity. Material and Methods: Two hundred patients with recurrence prostate cancer after initial treatment were distributed into four groups according to the following protocol: group 1 - open prostatectomy and androgen deprivation hormone therapy; group 2 - open prostatectomy combined with radiotherapy and androgen deprivation hormone therapy; group 3 - androgen deprivation hormone therapy alone; and group 4 - radiotherapy combined with androgen deprivation hormone therapy. All patients answered two questionnaires validated for Brazil related to the quality of life, the European Quality of Life Questionnaire and the International Index of Erectile Function. The presence of urinary tract infection, hematuria, hematochezia, urinary incontinence, and urethral stricture after the treatments were also investigated. The adverse effects reported in the four groups following the treatments were statistically compared and significance was considered indicated by p-values of <0.05.

Results: This study revealed worse mobility and self-care, greater limitations of usual activities, and a higher incidence of urinary incontinence and erectile dysfunction in patients who underwent prostatectomy. All these adverse effects were worse when the surgical procedure was associated with radiotherapy and androgen deprivation hormone therapy.

Conclusion: Prostatectomy is associated with complications, which are responsible for a worse quality of life due to mobility limitations, difficulty in self-care, urinary incontinence, and sexual dysfunction. All these adversities worsen when the surgery is combined with radiotherapy and androgen deprivation hormone therapy.

RESUMO

Introdução: Estudar a qualidade de vida após o tratamento do câncer tornou-se uma prioridade na oncologia. Objetivos: Avaliar o impacto de diferentes tratamentos para recidiva do câncer de próstata na qualidade de vida e na atividade sexual.

Material e Métodos: Duzentos pacientes com recidiva de câncer de próstata após tratamento inicial foram distribuídos em quatro grupos de acordo com o seguinte protocolo: grupo 1 - prostatectomia aberta e terapia hormonal de privação de androgênio; grupo 2 - prostatectomia aberta combinada com radioterapia e terapia hormonal de privação de androgênio; grupo 3 - terapia hormonal de privação de androgênio isoladamente; e grupo 4 - radioterapia combinada com terapia hormonal de privação de androgênio. Todos os pacientes responderam a dois questionários validados para o Brasil relacionados à qualidade de vida, o Questionário Europeu de Qualidade de Vida e o Índice Internacional de Função Erétil. Também foi investigada a presença de infecção do trato urinário, hematúria, hematoquezia, incontinência urinária e estenose uretral após os tratamentos. Os efeitos adversos relatados nos quatro grupos após os tratamentos foram comparados estatisticamente e a significância foi considerada indicada por valores de p<0,05.

Resultados: Este estudo revelou pior mobilidade e autocuidado, maiores limitações nas atividades habituais e maior incidência de incontinência urinária e disfunção erétil em pacientes submetidos à prostatectomia. Todos esses efeitos adversos foram piores quando o procedimento cirúrgico foi associado à radioterapia e à terapia hormonal de privação de androgênio.

Conclusão: A prostatectomia está associada a complicações, responsáveis por pior qualidade de vida devido a limitações de mobilidade, dificuldade no autocuidado, incontinência urinária e disfunção sexual. Todas essas adversidades pioram quando a cirurgia é combinada com radioterapia e terapia hormonal de privação androgênio.

Keywords:

Quality of life - Erectile dysfunction - Prostatectomy - Radiotherapy

Descritores:

Qualidade de vida - Disfunção erétil - Prostatectomia - Radioterapia


Publication History

Received: 06 August 2023

Accepted: 11 October 2023

Article published online:
29 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Fernando Parma Marsicano, Andy Petroianu. Impact of advanced prostatic cancer treatment on quality of life and sexual function. Brazilian Journal of Oncology 2023; 19: e-20230438.
DOI: 10.5935/2526-8732.20230438
 

  • REFERÊNCIAS BIBLIOGRÁFICAS

  • 1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72 (01) 7-33
    Search in Google Scholar
  • 2 Klotz L. Active surveillance for intermediate risk prostate cancer. Curr Urol Rep 2017; 18: 80
    Search in Google Scholar
  • 3 Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh RRPC. Natural history of progression after PSA. J Am Med Assoc 1999; May 281 (17) 1591-7
    Search in Google Scholar
  • 4 Matsumoto K, Niwa N, Hattori S, Takeda T, Morita S, Kosaka T. et al. Establishment of the optimal follow-up schedule after radical prostatectomy. Urol Oncol 2018; Jul 36 (07) e341
    Search in Google Scholar
  • 5 Van Der Veen JH, Van Andel G, Kurth KH. Quality-of-life assessment in bladder cancer. World J Urol 1999; Aug 17 (04) 219-24
    Search in Google Scholar
  • 6 Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP. et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 2017; Mar 317 (11) 1141-50
    Search in Google Scholar
  • 7 Lardas M, Liew M, Van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T. et al. Quality of life outcomes after primary treatment for clinically localised prostate cancer. Eur Urol 2017; Dec 72 (06) 869-85
    Search in Google Scholar
  • 8 Bellardita L, Valdagni R, Van den Bergh R, Randsdorp H, Repetto C, Venderbos LD. et al. How does active surveillance for prostate cancer affect quality of life?. Eur Urol 2015; Apr 67 (04) 637-45
    Search in Google Scholar
  • 9 Vernooij RW, Lancee M, Cleves A, Dahm P, Bangma CH, Aben KK. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database Syst Rev 2020; Jun 6 (06) CD006590
    Search in Google Scholar
  • 10 Van den Broeck T, Van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D. et al. Biochemical recurrence in prostate cancer: the european association of urology prostate cancer guidelines panel recommendations. Eur Urol Focus 2020; Mar 6 (02) 231-4
    Search in Google Scholar
  • 11 Kind P, Pickard AS. Interim scoring for the EQ-5D-5L. 2012; Jul/Aug 15 (05) 708-15
    Search in Google Scholar
  • 12 Butler CC, Hawking MK, Quigley A, McNulty CA. Incidence, severity, help seeking and management of uncomplicated urinary tract infection. Br J Gen Pract 2015; 65 (639) e702-e7
    Search in Google Scholar
  • 13 Averbeck MA, Woodhouse C, Comiter C, Bruschini H, Hanus T, Herschorn S. et al. Surgical treatment of post-prostatectomy stress urinary incontinence in adult men. Neurourol Urodyn 2019; Jan 38 (01) 398-406
    Search in Google Scholar
  • 14 Cotta BH, Buckley JC. Endoscopic treatment of urethral stenosis. Urol Clin North Am 2017; Feb 44 (01) 19-25
    Search in Google Scholar
  • 15 Gamst-Klaussen T, Lamu AN. Does the EQ-5D usual activities dimension measure what it intends to measure?. Qual Life Res 2020; 29 (09) 2553-62
    Search in Google Scholar
  • 16 Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; Aug 14 (04) 226-44
    Search in Google Scholar
  • 17 Shevach J, Weiner A, Morgans AK. Quality of life-focused decision-making for prostate cancer. Curr Urol Rep 2019; Aug 20 (10) 57
    Search in Google Scholar
  • 18 Magee DE, Singal RK. Androgen deprivation therapy: indications, methods of utilization, side effects and their management. Can J Urol 2020; 27 27 Suppl 1 11-6
    Search in Google Scholar
  • 19 Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Walsh EI. et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol 2020; Mar 77 (03) 320-30
    Search in Google Scholar
  • 20 Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E. et al. Quality of life in men living with advanced and localised prostate cancer in the UK. Lancet Oncol 2019; Mar 20 (03) 436-47
    Search in Google Scholar
  • 21 Heesakkers J, Farag F, Bauer RM, Sandhu J, De Ridder D, Stenzl A. Pathophysiology and contributing factors in postprostatectomy incontinence. Eur Urol 2017; Jun 71 (06) 936-44
    Search in Google Scholar
  • 22 Schifano N, Capogrosso P, Tutolo M, Dehò F, Montorsi F, Salonia A. How to prevent and manage post-prostatectomy incontinence. World J Mens Health 2021; Oct 39 (04) 581-97
    Search in Google Scholar
  • 23 Cozzarini C, Rancati T, Palorini F, Avuzzi B, Garibaldi E, Balestrini D. et al. Patient-reported urinary incontinence after radiotherapy for prostate cancer. Radiother Oncol 2017; 125 (01) 101-6
    Search in Google Scholar
  • 24 Izard JP, Siemens DR. Androgen deprivation therapy and mental health: impact on depression and cognition. Eur Urol Focus 2020; Nov 6 (06) 1162-4
    Search in Google Scholar
  • 25 Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK. et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol 2016; 34 (16) 1905-12
    Search in Google Scholar
  • 26 Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fossa SD. Can sexual bother after radical prostatectomy be predicted preoperatively?. BJU Int 2012; May 109 (09) 1366-74
    Search in Google Scholar
  • 27 Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR. et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction. Cancer 2014; Feb 120 (08) 1263-71
    Search in Google Scholar
  • 28 Bhat KRS, Raghunath SK, Srivatsa N, Tejus C, Vishruth K, Kumar RA. Outcomes of minimally invasive radical prostatectomy-a contemporary review. Indian J Surg Oncol 2020; Jun 11 (04) 580-8
    Search in Google Scholar
  • 30 Corona G, Filippi S, Comelio P, Bianchi N, Frizza F, Dicuio M. et al. Sexual function in men undergoing androgen deprivation therapy. Int J Impot Res 2021; May 33 (04) 439-47
    Search in Google Scholar